• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SEIKAGAKU CORPORATION GEL-ONE; ACID, HYALURONIC, INTRAARTICULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SEIKAGAKU CORPORATION GEL-ONE; ACID, HYALURONIC, INTRAARTICULAR Back to Search Results
Model Number 00-1111-001-00
Device Problem Insufficient Information (3190)
Patient Problems Syncope (1610); Itching Sensation (1943); Rash (2033)
Event Date 02/03/2020
Event Type  Injury  
Manufacturer Narrative
This case is received by seikagaku corporation on february 28, 2020 from the fda as mw5092945 dated february 24, 2020.We attempt to contact the reporter through our us partner.
 
Event Description
On (b)(6) 2020: a female patient received gel-one injection to the knee for osteoarthritis.Shortly following the injection at the md office, she fainted.She developed a severe itch and rash, and experienced chest pain.She was treated by emergency medical technicians and rushed to a hospital.On (b)(6) 2020: the patient was discharged with benadryl 50 mg.
 
Manufacturer Narrative
According to our us partner on may 12, 2020 no additional information was available in contact attempts on march 31, may 11.In the 2nd follow-up, the customer informed that they don't have additional information, hence the 3rd follow-up was not done.This case is received by seikagaku corporation on february 28, 2020 from the fda as mw5092945 dated february 24, 2020.We selected the code of 4316 (appropriate term/code not available) for h.6 manufacturer evaluation conclusion code, because the reported adverse event was not listed in the package insert and concerned lot number was not available.
 
Event Description
(b)(6) 2020 - a female patient received gel-one injection to the knee for osteoarthritis.Shortly following the injection at the md office, she fainted.She developed a severe itch and rash, and experienced chest pain.She was treated by emergency medical technicians and rushed to a hospital.(b)(6) 2020 - the patient was discharged with benadryl 50 mg.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GEL-ONE
Type of Device
ACID, HYALURONIC, INTRAARTICULAR
Manufacturer (Section D)
SEIKAGAKU CORPORATION
marunouchi center building
6-1, marunouchi 1-chome
chiyoda-ku, tokyo 100-0 005
JA  100-0005
MDR Report Key9824290
MDR Text Key190516336
Report Number9612392-2020-00004
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
PMA/PMN Number
P080020
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer
Type of Report Initial,Followup
Report Date 02/28/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/12/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model Number00-1111-001-00
Device Catalogue Number00-1111-001-00
Was Device Available for Evaluation? No
Date Manufacturer Received02/28/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Hospitalization;
-
-